enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) was the recipient of a significant growth in short interest in the month of September. As of September 15th, there was short interest totalling 216,700 shares, a growth of 38.7% from the August 31st total of 156,200 shares. Based on an average daily volume of 123,800 shares, the days-to-cover ratio is currently 1.8 days. Currently, 1.3% of the shares of the company are sold short.
enGene Stock Performance
ENGN traded up $0.55 on Friday, hitting $6.05. 432,716 shares of the stock traded hands, compared to its average volume of 99,694. The business has a fifty day moving average price of $7.00 and a two-hundred day moving average price of $10.78. The company has a current ratio of 19.52, a quick ratio of 19.52 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $267.20 million, a PE ratio of -3.52 and a beta of -0.68. enGene has a 52 week low of $4.42 and a 52 week high of $43.00.
enGene (NASDAQ:ENGN – Get Free Report) last released its quarterly earnings data on Tuesday, September 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. On average, research analysts predict that enGene will post -1.64 EPS for the current fiscal year.
Institutional Investors Weigh In On enGene
Wall Street Analysts Forecast Growth
ENGN has been the topic of a number of research analyst reports. Oppenheimer reiterated an “outperform” rating and issued a $30.00 target price on shares of enGene in a research note on Tuesday, September 24th. Morgan Stanley reaffirmed an “overweight” rating and issued a $40.00 price target on shares of enGene in a research report on Wednesday, September 11th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, enGene presently has an average rating of “Buy” and a consensus price target of $33.67.
View Our Latest Stock Report on enGene
enGene Company Profile
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
See Also
- Five stocks we like better than enGene
- What are earnings reports?
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- What does consumer price index measure?
- CarMax’s Impressive Rally: What Investors Should Watch Next
- How to Effectively Use the MarketBeat Ratings Screener
- MarketBeat Week in Review – 9/23 – 9/27
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.